Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Herriot Tabuteau also recently made the following trade(s):
- On Wednesday, August 5th, Herriot Tabuteau sold 45,004 shares of Axsome Therapeutics stock. The stock was sold at an average price of $212.01, for a total transaction of $9,541,298.04.
- On Wednesday, July 1st, Herriot Tabuteau sold 49,666 shares of Axsome Therapeutics stock. The shares were sold at an average price of $240.25, for a total transaction of $11,932,256.50.
- On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The shares were sold at an average price of $241.01, for a total transaction of $11,970,966.70.
Axsome Therapeutics Stock Performance
AXSM stock traded up $2.61 during trading on Friday, reaching $212.74. 1,024,411 shares of the stock were exchanged, compared to its average volume of 766,407. Axsome Therapeutics, Inc. has a twelve month low of $102.67 and a twelve month high of $260.19. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market capitalization of $10.95 billion, a P/E ratio of -57.03 and a beta of 0.65. The stock has a 50 day simple moving average of $237.39 and a 200-day simple moving average of $203.90.
Hedge Funds Weigh In On Axsome Therapeutics
A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in Axsome Therapeutics by 14.9% during the 2nd quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock worth $85,000 after buying an additional 45 shares in the last quarter. Birchview Capital LP grew its holdings in shares of Axsome Therapeutics by 1.0% in the 4th quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock valued at $1,107,000 after acquiring an additional 61 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Axsome Therapeutics by 3.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock valued at $351,000 after acquiring an additional 65 shares in the last quarter. Xponance LLC increased its position in shares of Axsome Therapeutics by 2.4% in the fourth quarter. Xponance LLC now owns 3,265 shares of the company’s stock valued at $596,000 after acquiring an additional 76 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of Axsome Therapeutics by 7.2% in the first quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after acquiring an additional 79 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the company. Mizuho cut their target price on Axsome Therapeutics from $310.00 to $306.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. UBS Group boosted their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a report on Friday, April 10th. Piper Sandler restated an “overweight” rating and issued a $258.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Finally, Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $265.55.
Check Out Our Latest Stock Analysis on AXSM
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome’s pipeline includes several late-stage and approved product candidates.
Featured Articles
- Five stocks we like better than Axsome Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
